Key Takeaways:
Odyssey Therapeutics Inc., a clinical-stage biopharmaceutical company, priced its upsized initial public offering of 15.5 million shares at $18.00 per share, raising approximately $304 million in gross proceeds when combined with a concurrent private placement. The Boston-based company is focused on developing medicines for autoimmune and inflammatory diseases.
The details of the offering were outlined in a company press release, which also disclosed a concurrent sale of 1,388,889 shares to an affiliate of TPG Life Sciences Innovations at the IPO price.
The offering was upsized from its initial filing, indicating strong investor demand. The gross proceeds of approximately $304 million do not factor in the underwriters' 30-day option to purchase up to an additional 2,325,000 shares. The IPO is expected to close on May 11, 2026, with shares trading on the Nasdaq under the ticker "ODTX" starting May 8. J.P. Morgan, TD Cowen, and Cantor are acting as joint book-running managers.
The successful pricing comes amid a busy week for new listings, including the strong debut of defense-tech firm HawkEye 360 and organic juice maker Suja Life. Another biotech, Viridian Therapeutics, also announced a significant capital raise, showing continued investor interest in the sector despite market volatility. For Odyssey, the capital raised is expected to fund the advancement of its internally discovered portfolio of medicines.
This article is for informational purposes only and does not constitute investment advice.
